WO2024241094 - IDENTIFICATION OF NOVEL MARKERS FOR BREAST CANCER CTC CHARACTERIZATION
National phase entry:
Publication Number
WO/2024/241094
Publication Date
28.11.2024
International Application No.
PCT/IB2024/000289
International Filing Date
21.05.2024
Title **
[English]
IDENTIFICATION OF NOVEL MARKERS FOR BREAST CANCER CTC CHARACTERIZATION
[French]
IDENTIFICATION DE NOUVEAUX BIOMARQUEURS POUR LA CARACTÉRISATION DE CTC DU CANCER DU SEIN
Applicants **
SCREENCELL S.A.
62, rue de Wattignies
75012 Paris, FR
Inventors
NASERIAN, Sina
62, rue de Wattignies
75012 Paris, FR
Priority Data
63/468,041
22.05.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2010 | |
| EPO | Filing, Examination | 12367 | |
| Japan | Filing | 597 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 7710 |
Total: 23259 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein are methods for identifying breast cancer in a subject, the methods comprising providing a biological sample from the subject and determining a differential level of at least one biomarker, wherein the differential level of the at least one biomarker compared to a healthy control or a reference value is indicative for the presence of breast cancer in the subject.[French]
L'invention propose des procédés d'identification du cancer du sein chez un sujet, les procédés comprenant la fourniture d'un échantillon biologique provenant du sujet et la détermination d'un niveau différentiel d'au moins un biomarqueur, le niveau différentiel de l'au moins un biomarqueur par rapport à un témoin sain ou à une valeur de référence indiquant la présence d'un cancer du sein chez le sujet.